JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A1987 Ki16425
4 Citation

Target: LPA Receptors

Summary: LPA receptor antagonist

≥23.75 mg/mL
B1511 Mifepristone
3 Citation

Target: Progesterone Receptors|Glucocorticoid Receptors

Summary: Progesterone receptor antagonist

≥21.48 mg/mL
B2240 Olanzapine

Target: 5-HT2 Receptors|D2 Receptors

Summary: Antagonist of 5-HT2A and dopamine D2 receptors

insoluble in H2O; ≥15.6 mg/mL
B1466 WZ811

Target: CXCR

Summary: Competitive CXCR4 antagonist,highly potent

insoluble in H2O; insoluble in EtOH; ≥15.02 mg/mL
B1465 Plerixafor 8HCl (AMD3100 8HCl)

Target: CXCR

Summary: CXCR4 antagonist

≥155.4 mg/mL
B1214 Perindopril

Target: Angiotensin-Converting Enzymes (ACEs)

Summary: ACE inhibitor

Soluble in DMSO
B2231 Amitriptyline HCl

Target: Trk Receptors|5-HT2 Receptors|Norepinephrine transporter|5-HT Transporters

Summary: Serotonin /norepinephrine receptor/5-HT4/5-HT2 inhibitor

≥15.69 mg/mL
B1591 Ki16198

Target: LPA Receptors

Summary: LPA antagonist
B1986 Nedaplatin

Summary: DNA synthesis inhibitor

insoluble in DMSO; insoluble in EtOH; ≥9.8 mg/mL
B3587 kobe2602

Summary: Ras inhibitor

insoluble in H2O; ≥17 mg/mL